A synthesis of suppressed clinical science, the New Biology of cancer stem cells, quantum bioenergetics, and the epigenetic framework that reframes the entire oncology paradigm -- and what it means for the hundreds of thousands facing this diagnosis today.

NOTE

This article synthesizes over a decade of primary research literature alongside investigative commentary from GreenMedInfo.com (2012-2025), Sayer Ji's Substack, and expanded theoretical frameworks from REGENERATE (Hay House, 2020). It references peer-reviewed studies and does not constitute medical advice. Citations are numbered and listed at the end of this document.

There is a question that oncology has never answered cleanly, and that its institutional architecture is structurally designed to prevent from being asked: what if the primary treatments for cancer -- chemotherapy and radiotherapy -- are, in a measurable and mechanistically understood way, making cancer worse?

Not "worse" in the colloquial sense that patients feel terrible during treatment, though that too is undeniable. "Worse" in the precise biological sense: that these treatments, while producing the radiographic appearance of success -- a shrinking tumor, declining markers -- may be simultaneously selecting for a more aggressive, metastasis-prone, treatment-resistant cancer that will ultimately kill the patient far more efficiently than the original disease would have.

This is not fringe conjecture. It is, at this point, a finding established across multiple independent research programs, published in the most prestigious biomedical journals in the world -- Science Translational Medicine, Cancer, Stem Cells, Nature Medicine, the Journal of Clinical Oncology -- and yet it occupies exactly zero square footage in the oncology consultation room where patients are being told to begin chemotherapy this week.

Understanding this gap -- between what the peer-reviewed literature now establishes and what is communicated to patients -- requires understanding something deeper: the entire conceptual framework through which we understand cancer may be fundamentally wrong. And it is the New Biology -- a revolution in our understanding of epigenetics, quantum bioenergetics, the microbiome, and the informational nature of living systems -- that provides both the explanation for why conventional treatment fails, and a radically different path forward.

Part One: The Old Biology That Got Us Here

The dominant theory governing modern oncology is the somatic mutation theory of cancer: the view that cancer is fundamentally a disease of accumulated DNA mutations that dysregulate cell division and survival. This positions cancer as a random, unfortunate breakdown of cellular machinery -- and it positions chemotherapy and radiation as logical interventions because they target the rapidly dividing cells that mutational cascade produces.

But as Sayer Ji wrote in REGENERATE, "the idea that your body is inherently defective and will eventually be broken beyond repair is categorically incorrect." The somatic mutation theory suffers from a foundational problem: it positions the patient as a passive victim of genetic misfortune, while ignoring the overwhelming evidence that cancer arises from -- and is sustained by -- modifiable environmental, epigenetic, and metabolic conditions.

The Human Genome Project delivered a devastating blow to genetic determinism. Scientists expected to find at least 100,000 human genes -- one per protein -- but found only 20,000 to 25,000 protein-coding genes, with the latest estimates paring this to roughly 18,000. Earthworms have 20,470. Tomatoes have 31,760. The simplistic one-gene-one-disease model has collapsed under its own weight, yet it continues to govern clinical oncology as if the evidence never arrived.

The paradigm that has replaced it -- epigenetics -- reveals that cancer is not primarily a story of broken DNA, but of broken signaling: environmental variables, dietary exposures, toxic burdens, emotional states, and microbiome disruptions that alter which genes are expressed and which are silenced. As a PLoS One review concluded: "Genetic Factors Are Not the Major Causes of Chronic Diseases." [Ref 10] Studies connect cancers of nearly all types to epigenetic mechanisms -- meaning they are, in principle, reversible.

Cancer as Ancient Survival Program

An alternative framework -- increasingly supported by molecular biology, evolutionary medicine, and the New Biology -- proposes that cancer is better understood as an ancient survival program: a highly conserved genetic and metabolic toolkit that evolved billions of years ago to allow cells to survive environmental extremes -- hypoxia, acidosis, genotoxic chemical exposure, radiation, nutrient deprivation.

The germline cells within our bodies -- sperm and ovum -- represent what Sayer Ji describes as "a quasi-immortal and unbroken biological thread connecting us, through a near-infinite number of cell divisions, to the last universal common ancestor (LUCA), estimated to have emerged some 3.5 to 3.8 billion years ago." Cancer stem cells, as we will explore, appear to access this same ancient biological toolkit -- drawing on survival mechanisms that predate complex multicellular life.

If this framework is correct, chemotherapy and radiation do not merely fail to address the conditions that activated the "survival program" -- they actively intensify those conditions. Genotoxic stress, cellular damage, immune suppression, hypoxia, and metabolic disruption are precisely the environmental pressures under which the survival program evolved. We are, in a very real sense, creating better and better conditions for cancer to express its most aggressive adaptive capacities.

Part Two: The Telegraph Moment -- When the Evidence Could No Longer Be Hidden

On July 6, 2017, the UK's Telegraph published a headline that should have changed everything: "Chemotherapy may spread cancer and trigger more aggressive tumours, warn scientists." The article reported on a landmark study published in Science Translational Medicine by Dr. George Karagiannis and colleagues at the Albert Einstein College of Medicine.

The Karagiannis study examined the effects of neoadjuvant chemotherapy -- administered before surgical tumor removal, a now-standard protocol -- on the microscopic infrastructure of metastasis. Three of the most commonly used agents -- doxorubicin, paclitaxel, and cyclophosphamide -- when administered to breast cancer patients, caused a significant increase in all three of the following:

TMEM Activation: Increased activity of Tumor Microenvironment of Metastasis portals -- microscopic gateways through which cancer cells enter the bloodstream.

MENAINV Upregulation: Elevated expression of MENAINV, an isoform specifically associated with invasive and migratory cancer cell behavior -- a hallmark of what cancer biologists call epithelial-mesenchymal transition (EMT).

Circulating Tumor Cells: Higher counts of circulating tumor cells in the bloodstream -- the biological currency of metastasis and distant organ seeding.

The tumor shrank. The cancer spread. The primary endpoint improved. The patient's survival prospects worsened. The researchers also demonstrated that the pro-metastatic effect was reversible -- either by administering a TMEM-blocking drug (rebastinib) or by genetically silencing the MENA gene. This is not a biological inevitability. It is a pharmacological mechanism with known targets. The question is why this finding has not restructured clinical practice.

The answer, as in so many instances of inconvenient medical science, has to do with economics. As Sayer Ji documents in REGENERATE, citing an internal Goldman Sachs report, the cancer industry's analysts have explicitly noted that cancers with a stable "incident pool" -- meaning a reliable, replenishable patient population -- pose less risk to sustained revenue than diseases for which cures are achievable. "Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise," analyst Salveen Richter wrote. A treatment that promotes metastasis while appearing to reduce tumor volume is, from this perspective, a more reliably profitable outcome than one that produces durable remission.

2× Chemotherapy doubled the number of cancer cells in the bloodstream and lungs in key experimental models. This pro-metastatic effect was mediated through TMEM portal activation -- a mechanism completely invisible to the standard tumor volume metrics used to declare treatment success.

Source: Karagiannis et al. · Science Translational Medicine 9(397):eaan0026, 2017

If the chemotherapy findings disturb, the radiation findings are, in some ways, more alarming -- because radiation is positioned as the more "targeted" and "precise" intervention. The precision is real. What happens to the cells that survive that precision is not discussed.

In July 2012, researchers from the UCLA Jonsson Comprehensive Cancer Center's Department of Radiation Oncology published findings in the journal Cancer titled: "Radiation Treatment Generates Therapy Resistant Cancer Stem Cells From Aggressive Breast Cancer Cells." The key finding: even when radiation killed half the tumor cells treated, the surviving cells -- designated induced breast cancer stem cells (iBCSCs) -- were up to 30 times more likely to form tumors than non-irradiated breast cancer cells. Not 30% more. Three thousand percent more.

A concurrent study published in Stem Cells (PMID 22489015, May 2012) deepened the finding: ionizing radiation was shown to actively reprogram less malignant breast cancer cells into induced cancer stem cells. Radiation was not merely selecting for pre-existing aggressive cells -- it was manufacturing new ones through a process of epigenetic dedifferentiation. This is a phenomenon with a precise molecular analog in what REGENERATE calls the New Biology: the same epigenetic machinery through which environmental exposures remodel gene expression is being commandeered by radiation to transform relatively benign cancer cells into the most dangerous cells in the tumor.

Parallel findings emerged in prostate cancer. A 2012 study published in Prostate (PMID 22513891) demonstrated that long-term recovery following radiotherapy was associated with an increase in cancer stem cells. A companion study (PMID 22438320, Stem Cells) showed that stem-like cells with luminal progenitor phenotype survived castration therapy in human prostate cancer -- helping explain why androgen deprivation, the standard follow-up to radiation, so reliably fails to produce durable remissions.

The logic of standard radiotherapy -- kill as many tumor cells as possible, watch the tumor shrink, declare partial victory -- breaks down completely when viewed through this lens. What is called a response to treatment may be, biologically, the creation of a more dangerous cancer. The regressing tumor volume creates a false signal of efficacy while the surviving cell population undergoes a forced evolutionary leap toward maximum malignancy.

Part Four: Cancer Stem Cells -- The Invisible Hierarchy the Standard of Care Ignores

To understand why conventional cancer treatments make cancer worse, one must understand the biology of cancer stem cells -- a population that represents, depending on the tumor type, fewer than one in ten thousand cells in a given cancer, yet which holds virtually all of the cancer's regenerative power.

The cancer stem cell hypothesis -- rigorously established beginning with Lapidot and colleagues' 1994 Nature Medicine paper on acute myeloid leukemia -- proposes that tumors are not homogeneous masses of equivalently dangerous cells, but hierarchically organized systems in which a small population of stem-like cells sits atop the hierarchy, giving rise to the bulk of the tumor's differentiated daughter cells.

This hierarchy mirrors what the New Biology has established about the body's normal stem cell architecture. As REGENERATE documents, the body's innate regenerative capacity is mediated by stem cells that retain the ability to repopulate damaged tissue: every four to five days, intestinal stem cells repopulate the entire villous epithelium; every two months, basal layer stem cells regenerate the entire epidermis. Cancer stem cells have co-opted this same regenerative machinery -- and turned it against the host.

Cancer stem cells are, by their nature, slow-dividing. They are therefore almost entirely resistant to treatments that target rapidly dividing cells. They are equipped with active multidrug-resistance machinery -- efflux pumps, anti-apoptotic proteins -- that allow them to survive chemical assault. They evade immune surveillance through surface protein modifications. They can remain dormant for years in distant organ niches before reactivating with full tumorigenic capacity.

The tragedy is precise: standard treatment kills the cells that were never going to kill the patient efficiently, while leaving -- and in some cases, actively enriching -- the cells that will. As REGENERATE frames it: treatments that appear to work are in fact performing a kind of inverse biological triage, eliminating the soldiers while promoting the generals.

The Fractional Kill Problem

The treatment protocol known as "fractional kill" -- standard chemotherapy cycles designed to kill a percentage of cells per cycle -- compounds this problem with mathematical inevitability. The first round of chemotherapy kills only a fraction of all tumor cells. Repeated cycles attempt to regress the tumor without killing the patient. But each cycle preferentially kills the faster-dividing, less dangerous daughter cells -- increasing the ratio of CSCs to benign differentiated cells with every treatment cycle. The tumor that re-emerges after six cycles of chemotherapy is not the same tumor that was present before treatment began. It is, in every measurable biological sense, a more malignant cancer.

This is not an unfortunate side effect. It is a mathematical and biological consequence of the foundational mechanism of the treatment. As Sayer Ji wrote in 2012: "The reality is that the chemotherapy, even though it has reduced the tumor volume, by increasing the ratio of CSCs to benign daughter cells, has actually made the cancer more malignant."

Part Five: Eight Converging Mechanisms -- A Complete Biological Picture

The science does not point to a single mechanism by which conventional treatment worsens cancer biology. It points to at least eight distinct, independently established pathways -- each with its own body of peer-reviewed evidence, each operating simultaneously in treated patients:

Part Six: The Carcinogen Paradox -- Treating Cancer With Cancer-Causing Drugs

Perhaps the deepest conceptual contradiction in modern oncology is this: the dominant scientific theory of cancer causation holds that cancer begins with genotoxic damage -- DNA-damaging events that initiate malignant transformation. Chemotherapy agents are, by mechanism, genotoxic. That is their therapeutic rationale: they damage DNA, hoping that cancer cells will be more susceptible to this damage than normal cells.

Cyclophosphamide, a standard component of breast cancer regimens, is classified by the International Agency for Research on Cancer (IARC) as a Group 1 human carcinogen -- meaning the evidence for its carcinogenicity in humans is unambiguous. Doxorubicin causes double-strand DNA breaks. Paclitaxel disrupts mitosis in all fast-dividing cells -- cancer, immune, GI lining, and developing pediatric tissue alike.

Tamoxifen -- the first-line hormonal therapy for estrogen-receptor-positive breast cancer, used by millions of women worldwide -- is similarly classified as a human carcinogen by both the WHO and the American Cancer Society, with documented risk of endometrial and hepatocellular carcinoma. The standard defense is that the benefit outweighs the risk in defined populations. But this defense collapses entirely when the full scope of treatment-induced malignancy -- including cancer stem cell enrichment and TMEM-mediated metastasis promotion -- is incorporated into the risk-benefit calculation. That calculation has never been formally performed.

The New Biology provides a framework for understanding why this genotoxic paradox is not merely an unfortunate side effect but a predictable consequence of misaligned therapeutic logic. As REGENERATE documents, the epigenetic field -- the totality of regulatory signals that govern gene expression -- is exquisitely sensitive to genotoxic stress. When DNA-damaging agents flood the cellular environment, they do not merely kill cells: they reprogram the epigenetic landscape of surviving cells, activating survival programs, stress response pathways, and -- critically -- the stem cell self-renewal machinery that cancer stem cells depend on.

The BRCA Narrative and Prophylactic Harm

The rhetoric around BRCA gene variants provides a particularly instructive case study. As REGENERATE documents in detail, the assertion that BRCA1 or BRCA2 status constitutes a near-certain cancer death sentence has led some -- including celebrity Angelina Jolie -- to have breast tissue and ovaries excised prophylactically. Yet according to The Lancet Oncology, women with either gene variant are not more likely to die from treatment-resistant breast cancers than other women diagnosed with the disease; in fact, they have higher survival rates than women without the BRCA "mutations" treated for the same cancer. [Ref 28]

More than a thousand polymorphisms in the BRCA1 and BRCA2 genes have been identified, some of which are inversely related to breast cancer risk. The BRCA1 subtype K1183R, for instance, is associated with increased breast cancer survival. [Ref 29] These are not edge cases -- they are evidence that the seductive BRCA-causes-breast-cancer narrative is a gross oversimplification that has led to surgical interventions of extraordinary magnitude based on statistical models that cannot withstand scrutiny.

What the BRCA narrative most dangerously obscures is the role of epigenetic exposures -- micronutrient deficiencies, chemical exposures, radiation, emotional stress -- that can "knock out" the cancer-protective function of the BRCA genes regardless of whether one was born with a so-called "defective" or "healthy" version of the gene. As REGENERATE puts it: "surgically removing organs to prevent lesions from forming makes just about as much sense as decapitation to prevent a headache."

In 2004, the Journal of Clinical Oncology published a systematic analysis by Morgan, Ward, and Barton: "The Contribution of Cytotoxic Chemotherapy to 5-Year Survival in Adult Malignancies." The study analyzed data from 22 major adult cancers in the United States and Australia, attempting to quantify the actual contribution of chemotherapy -- as distinct from surgery, radiation, hormonal therapy, and spontaneous remission -- to 5-year survival rates.

The finding: chemotherapy contributed to 5-year survival in approximately 2.3% of cases in the United States. In Australia, the figure was 2.1%. The solid tumors of the breast, colon, lung, pancreas, and prostate -- the cancers that kill the most people -- are precisely the cancers in which this analysis found the contribution of chemotherapy to survival to be at or near zero.

The authors themselves wrote: "To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the contribution of these drugs to cancer survival is urgently required." That urgently required evaluation has not occurred in the twenty years since this paper was published.

This silence is not scientific -- it is structural. As REGENERATE documents, the medical literature itself is deeply compromised: 50.6% of journal editors accept payments from industry sources, with an average payment of $28,136. [Ref 4] A 2007 national survey published in the New England Journal of Medicine found that 94% of physicians had ties to the pharmaceutical industry. [Ref 5] In a phenomenon known as the "file drawer effect," negative trials unfavorable to drugs are more likely to be suppressed. [Ref 3] Within this system, the 2.3% finding is not a scientific anomaly to be investigated -- it is a commercial inconvenience to be ignored.

If the failure of conventional treatment is mechanistically tied to its inability to target cancer stem cells, the logical direction of research is toward agents that do. This is precisely where the natural compounds literature becomes not merely interesting, but clinically urgent -- and where it connects most powerfully to the New Biology framework developed in REGENERATE.

GreenMedInfo's research database catalogs over 100 natural substances with demonstrated activity against cancer stem cells across peer-reviewed literature. What is remarkable about many of these compounds is not merely their anti-CSC activity, but their differential toxicity profile: they are selectively toxic to cancer cells while being protective of normal cells -- the exact inverse of the profile seen with cytotoxic chemotherapy.

To understand why this differential toxicity exists, we need the New Biology framework. REGENERATE introduces what is called the xenohormesis hypothesis: the proposition that animals have evolved to sense signaling and stress-induced molecules in the plants they consume in order to mount a preemptive defense to environmental adversity that increases the probability of their survival. Plants that produce compounds in response to environmental stress -- drought, UV radiation, pathogenic infection -- provide their animal consumers with chemical cues that activate resilience factors and pathways in the body. The polyphenols most studied as CSC inhibitors (resveratrol, curcumin, EGCG, quercetin) are precisely the compounds that stressed plants produce in greatest abundance. They are, in REGENERATE's framing, "stress signals from the plant kingdom, encoded in the molecular language of evolution, transmitted to the biological systems that learned to read them over millions of years of co-evolution."

Curcumin exemplifies this profile with unusual documentation depth. Medline catalogs over 4,500 studies on curcumin spanning 500+ disease states. Its LD50 is 2,000 mg/kg. 5-fluorouracil's LD50 is 115 mg/kg -- making the chemotherapy agent roughly 17 times more acutely toxic. Curcumin's anti-CSC mechanism operates through simultaneous downregulation of three key developmental pathways: Wnt, Notch, and Hedgehog -- the same pathways that billions in pharmaceutical research have targeted with novel agents, with largely disappointing and often toxic results. As the GreenMedInfo database documents, curcumin is associated with 57 chemosensitizing studies and 70 chemoprotective studies -- meaning it both enhances the efficacy of conventional treatment where it is used and protects normal tissue from its damage.

Epistemic note: The preponderance of these studies are in vitro or animal models. Human clinical trials for most of these compounds as standalone cancer treatments remain sparse -- not from a lack of mechanistic plausibility, but from a research economy in which the expected return on investment for an unpatentable plant compound is insufficient to motivate the required expenditure. As REGENERATE documents, this economic reality -- not the absence of evidence -- is the primary barrier between these findings and clinical application.

Food as Information: The miRNA Dimension

REGENERATE introduces a framework that extends the logic of phytochemical medicine beyond simple molecular biology: food is not just fuel and building blocks -- it is information. The microRNAs contained in whole plant foods -- virus-sized nucleic acid molecules packaged in exosomes secreted by plant cells -- survive the digestive process intact and function like software, altering the expression of our genes and biological pathways.

The implications for cancer are significant. Plant miRNAs have been shown to directly inhibit cancer cell proliferation through cross-kingdom gene regulation. A landmark study published in Cell Research demonstrated that plant miR159, found in cruciferous vegetables, directly inhibits breast cancer growth in vivo. [Ref: Chin et al., 2016] Another study showed grape exosome-like nanoparticles induce intestinal stem cells and protect against colitis. [Ref: Ju et al., 2013] Honeysuckle-encoded miR2911 was found to directly target influenza A viruses. [Ref: Zhou et al., 2015]

When we apply this framework to cancer treatment, the contrast becomes stark: chemotherapy introduces synthetic genotoxic molecules that the body recognizes as xenobiotics -- foreign and threatening. Natural phytochemical compounds deliver evolutionarily familiar information -- molecular signals that our biology has been reading and responding to for millions of years. The biological response to each category is fundamentally different, which may explain the differential toxicity profile that consistently emerges across the natural compounds literature.

The mechanisms described above operate with devastating efficiency when applied to real, progressive malignancies. They operate with even greater tragedy when applied -- as they routinely are -- to conditions that are not, in any clinically meaningful sense, cancers that would have harmed the patient.

Ductal carcinoma in situ (DCIS) -- detected by mammography and classified as "Stage 0" breast cancer -- is treated in approximately 97% of diagnosed cases with surgery, radiation, and often chemotherapy. Yet autopsy studies consistently find that between 7% and 39% of women who died of causes unrelated to breast cancer had DCIS-like lesions that were never detected and never caused harm. The prostate-specific antigen (PSA) screening story is similarly dramatic: the U.S. Preventive Services Task Force ultimately recommended against routine PSA screening after determining that harms from overdetection and overtreatment outweighed the benefits from early detection.

When a patient with a DCIS lesion -- one with perhaps a 20% statistical chance of ever progressing to invasive cancer -- is treated with radiation, and that radiation produces induced cancer stem cells thirty times more tumorigenic than their progenitors, the outcome is not ambiguous. The treatment created a cancer where previously there was only a risk. And when that patient later develops an aggressive, treatment-resistant breast cancer, the medical record will describe it as a "recurrence" -- not as a radiation-induced iatrogenic malignancy.

This is what Sayer Ji has called diagnostic laundering: the systematic reclassification of treatment-induced harms as disease progression, second primary tumors, or delayed-stage detection -- a linguistic and bureaucratic operation that makes iatrogenic causation invisible within the data systems that would otherwise document it. Iatrogenic cancers become new "incidents," boosting institutional cancer statistics. Harm from treatment is recast as biological inevitability.

REGENERATE frames this as a manifestation of what it calls "medical monotheism": the belief that there is only one true and right way to interpret and practice medicine, with alternative or competing methods deemed heretical despite evidence of being safer, more effective, and more readily available. Within this framework, evidence of iatrogenic harm is not incorporated into the model -- it is reclassified until it is unrecognizable.

REGENERATE introduces a theoretical framework for understanding cancer that goes deeper than both the somatic mutation theory and even the epigenetic model: the quantum bioenergetic perspective on cellular function. To understand why cancer cells behave the way they do -- and why conventional treatments may be making them worse -- requires understanding where cellular energy actually comes from and how cancer disrupts it.

As REGENERATE documents in its chapter on quantum biology, the conventional explanation for cellular energy -- ATP produced through aerobic and anaerobic respiration -- is insufficient to account for the actual energy output of the human cell. Dr. Douglas Wallace, considered the world's preeminent expert on mitochondria, has calculated that mitochondrial membranes, functioning as capacitors across their proton electrochemical gradient, produce electrical field strengths of up to 30 million volts per mitochondrion -- a voltage comparable to flares from the sun's surface. With up to 5,000 mitochondria per heart muscle cell, and trillions of cells in the body, the total potential energy available is effectively astronomical -- far beyond what ATP biochemistry can account for.

Army research scientist Goldfein's 1978 experiments demonstrated that mitochondria function not merely as energy transfer systems but as nano-scale particle accelerators -- with the helical structure of magnesium-bound ATP (MgATP) enabling the acceleration of hydrogen ions to relativistic speeds sufficient to transform target atoms into other elements. This biotransmutation phenomenon, first observed by French chemist Vauquelin in the 19th century and rigorously documented by Louis Kervran (nominated for a Nobel Prize in 1975), suggests that the healthy mitochondrion is a vastly more capable biological engine than conventional biochemistry acknowledges.

What does this have to do with cancer? The answer may be critical. Cancer cells are characterized by the Warburg effect: a shift from mitochondrial oxidative phosphorylation to glycolysis -- essentially, a downgrade from the highly sophisticated mitochondrial energy system to a more primitive, less efficient metabolic mode. In the New Biology framework, this is not a random metabolic dysfunction -- it is precisely the "ancient survival program" being activated: reverting to the metabolic toolkit that preceded complex mitochondrial evolution. Cancer cells operating in Warburg metabolism are, in a real sense, running on the ancient energy system that predates the mitochondrial endosymbiotic event 1.8 billion years ago.

Chemotherapy and radiation, by generating massive genotoxic stress, hypoxia, and immune disruption, create precisely the environmental conditions that favor Warburg-metabolizing, glycolytic cancer cells -- the most primitive, most aggressive, most treatment-resistant population. They simultaneously damage the mitochondrial sophistication of normal cells, degrading the very energy system that the body's own immune surveillance depends upon for anti-tumor function.

Conversely, many of the natural compounds that demonstrate the most compelling anti-CSC activity operate by restoring mitochondrial function and suppressing Warburg metabolism. Berberine, EGCG, and resveratrol all activate AMPK -- the cellular energy sensor that suppresses glycolysis and promotes mitochondrial function. Sulforaphane activates Nrf2 -- the master regulator of antioxidant defense that protects normal cell mitochondria while creating an inhospitable environment for cancer cell metabolism. These are not coincidental mechanisms. They are precisely targeted at the metabolic foundation of cancer's survival advantage.

Epigenetics, Grounding, and the Energetic Prerequisites for Healing

REGENERATE's framework extends beyond diet to encompass the full range of what it calls "paleo deficit disorder": the collective deficiency of ancestral environmental inputs in the modern industrialized landscape. Among these, two are particularly relevant to cancer: sunlight and grounding.

Research documented in REGENERATE shows that grounding -- direct physical contact between bare skin and the earth's surface -- allows the transfer of free electrons from the earth's near-infinite electron reservoir into the body's collagenous, liquid-crystalline semiconductor network. These electrons function as potent antioxidants, neutralizing the reactive oxygen species (ROS) that drive both cancer initiation and the genotoxic damage that chemotherapy uses as its therapeutic mechanism. As REGENERATE cites: "Electrons from the earth may in fact be the best antioxidants, with zero negative secondary effects, because our body evolved to use them over eons of physical contact with the ground." [Oschman et al., Journal of Inflammation Research, 2015]

Sunlight, similarly, is not merely a source of vitamin D -- it is, through melanin's photonic energy transduction, a potential contributor to cellular bioenergetics that REGENERATE explores in depth. Research documented in Cancer Biotherapy & Radiopharmaceuticals showed that melanin-rich mushrooms protected 90% of mice from lethal radiation doses, with the probable mechanism being melanin's ability to convert ionizing radiation into metabolic energy rather than allowing it to generate destructive free radicals. This finding has direct implications for radiation therapy: the same biological machinery that makes certain organisms radiation-resistant may be the machinery that radiation therapy, at its current dose levels, is overwhelming and destroying.

None of what has been presented here is a counsel of nihilism or a claim that no patient should ever receive conventional cancer treatment. In specific, well-documented contexts, chemotherapy and radiation provide genuine benefit that the available alternatives cannot match. Testicular cancer. Hodgkin's lymphoma. Childhood leukemia. These are real victories of cytotoxic oncology, and they deserve acknowledgment.

What intellectual honesty demands -- and what the evidence now makes impossible to responsibly avoid -- is this: the standard-of-care framework for the most common solid tumors is not producing the survival outcomes that the scale of its application would predict, and there are now well-characterized biological mechanisms that explain why. The enrichment of cancer stem cell populations. The activation of metastatic portals. The dedifferentiation of surviving cells into super-malignant phenotypes. The destruction of the immune system that would otherwise participate in the suppression of residual disease.

These mechanisms are not hypothesis. They are peer-reviewed findings from institutions that receive no funding from natural health advocates -- UCLA, Albert Einstein College of Medicine, published in Science Translational Medicine and Nature Medicine. And they now have a theoretical home in the New Biology: the epigenetic, quantum bioenergetic, and evolutionary medicine frameworks that REGENERATE documents provide a coherent account of why cancer stem cells resist treatment, why natural compounds target them preferentially, and why the conditions that conventional treatment creates are precisely the conditions most favorable to cancer's most dangerous adaptive modes.

The framework has radical implications for informed consent. Patients deserve to know that when the tumor shrinks on imaging, that image does not capture everything that is happening biologically. They deserve to know that the cancer stem cell population -- invisible to the scans used to measure response -- may be simultaneously expanding and becoming more dangerous. They deserve to know that natural compounds targeting these same stem cell populations exist, have significant mechanistic plausibility, have been shown in hundreds of peer-reviewed studies to modulate the pathways involved, and have been almost entirely excluded from clinical development by an economic system that cannot profit from them.

As REGENERATE articulates: "You don't have to rely on reductionist allopathic tinkering and troubleshooting, or become strangled by the choke-hold of pharmaceutical prescriptions -- you can rise victorious like a phoenix from the ashes when you veer back towards the ingredients that make for the recipe of a healthy body." That recipe, as both the New Biology and the natural compounds literature increasingly confirm, involves addressing cancer at the level of its epigenetic root causes -- not merely attacking its most visible cellular manifestations with agents that may be making the underlying disease worse.

Download a free chapter and buy REGENERATE here

Interested in learning more? Get access to the REGENERATE YOURSELF MASTERCLASS here

Cited Research & Sources

1.  Karagiannis GS et al. "Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism." Science Translational Medicine 9(397):eaan0026, 2017. DOI: 10.1126/scitranslmed.aan0026

2.  Knapton S. "Chemotherapy may spread cancer and trigger more aggressive tumours, warn scientists." The Telegraph, July 6, 2017.

3.  "Radiation Treatment Generates Therapy Resistant Cancer Stem Cells From Aggressive Breast Cancer Cells." Cancer, UCLA Jonsson Comprehensive Cancer Center, July 1, 2012.

4.  "Radiation-induced reprogramming of breast cancer cells." Stem Cells. 2012 May;30(5):833-44. PMID: 22489015.

5.  "Long-term recovery of irradiated prostate cancer increases cancer stem cells." Prostate. 2012. PMID: 22513891.

6.  "Stem-Like Cells with Luminal Progenitor Phenotype Survive Castration in Human Prostate Cancer." Stem Cells. 2012. PMID: 22438320.

7.  Morgan G, Ward R, Barton M. "The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies." Clinical Oncology. 2004;16(8):549-560. PMID: 15630849.

8.  Ji S. "Chemotherapy Makes Cancer Worse: The Evidence They Tried to Hide." Sayer Ji's Substack, July 9, 2025. sayerji.substack.com

9.  Ji S. "Does Chemo and Radiation Actually Make Cancer More Malignant?" GreenMedInfo.com, July 31, 2012.

10.  "Genetic Factors Are Not the Major Causes of Chronic Diseases." PLoS One. DOI: 10.1371/journal.pone.0154387

11.  Copson ER. "Germline BRCA Mutation and Outcome in Young-Onset Breast Cancer (POSH): A Prospective Cohort Study." The Lancet Oncology 29, no. 2 (2018): 169-180.

12.  BRCA1 subtype K1183R and increased breast cancer survival. NCBI PMID: 24600974.

13.  Oschman JL, Chevalier G, Brown R. "The effects of grounding (earthing) on inflammation, the immune response, wound healing, and prevention and treatment of chronic inflammatory and autoimmune diseases." Journal of Inflammation Research, 2015;8:83-96.

14.  Goldfein S. "Energy Development from Elemental Transmutations in Biological Systems." U.S. Army Report, 1978. apps.dtic.mil/dtic/tr/fulltext/u2/a056906.pdf

15.  Chin AR et al. "Cross-kingdom inhibition of breast cancer growth by plant miR159." Cell Research 26(2):217-228, 2016. DOI: 10.1038/cr.2016.13.

16.  Zhou Z, Li X, Liu J, et al. "Honeysuckle-encoded atypical microRNA2911 directly targets influenza A viruses." Cell Res. 2015;25(1):39-49.

17.  Richter S (Goldman Sachs). "The Genome Revolution" analyst report. Cited in REGENERATE, Hay House, 2020.

18.  Horton R. "Offline: What is medicine's 5 sigma?" The Lancet. 2015;385(9976):1380.

19.  50.6% journal editor payments: BMJ. 2017;359:j4619.

20.  94% of physicians with pharma ties: NEJM survey. 2007. NEJM doi: 10.1056/NEJMsa064508.

21.  Ji S. REGENERATE: Unlocking Your Body's Radical Resilience Through the New Biology. Hay House, 2020.

22.  GreenMedInfo Research Archive: "Anti-Therapeutic Action of Chemotherapy." greenmedinfo.com/anti-therapeutic-action/chemotherapy (120+ peer-reviewed studies).

23.  Wallace DC. "A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine." Annual Reviews in Genetics, 2005;39:359-407.

24.  Melanin-rich mushroom radiation protection: Cancer Biotherapy & Radiopharmaceuticals. PMID: 22968190.

25.  Xenohormesis hypothesis: Hooper PL et al. Lancet. 2010. PMID: 26949380.